Searched for
MOMENTA PHARMACEUTICALS
Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...- Patent infringement lawsuit filed against Natco by Johnson & Johnson, MomentaHomegrown pharma firm Natco on Wednesday said Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit agains...
- Culture of ‘bending rules’ in India challenges U.S. drug agencyThe US drug agency is bewildered with Indian pharma industry's culture of getting things done at all costs.
- Oncology solutions company Mitra Biotech gets $40 millionBoston and Bengaluru-based Mitra Biotech develops and provides novel technologies that personalise cancer treatment.
- Mitra Biotech raises $27.4 million in Series B funding led by Sequoia India"These new funds will allow us to enhance our technology and engage in new studies to further demonstrate CANScript’s clinical utility," sa...
- Indian-origin hedge fund manager charged with insider tradingSanjay Valvani, 44, reaped unlawful profits of nearly $32 million for hedge funds investing in health care securities by insider trading.
- We're here to stay, open to buy right portfolio: Rajiv Malik, President, MylanMylan is committed to staying in India and plans to build up its presence gradually while remaining open to acquisition, says Rajiv Malik.
- US court finds Teva's Copaxone patent invalid again: Natco PharmaNatco Pharma, a city-based drug maker, today said the US Court of Appeals for Federal Court has again found one of the patents of Teva's Co...
- Teva offers to buy Mylan for $40.1 billionTeva, the world’s biggest maker of generic medicines, offered $82 a share in cash and stock for Mylan, according to a statement.
- Setback to Natco pharma; US Supreme Court sends Teva patent case to Federal CircuitThe US Supreme Court has sent back the patent case related to Teva's multiple sclerosis drug Copaxone for a review by the Federal Circuit.
- Teva may move court against Dr Reddy's for patent infringementThe Israeli drug maker already is involved in various legal battles with other drug firms over the patent litigations of Copaxone.
- Natco Pharma cracks 19% as US justices agrees to hear Teva's Copaxone appealThe decision by the Supreme Court comes at a time when Teva is switching its daily version of Copaxone to twice a week version.
- Natco Pharma rallies over 8% as US Court rejects stay request on CopaxoneShares of Natco Pharma surged higher after the US Supreme Court rejected rival Teva Pharma’s request for stay on Copaxone drug.
- Natco Pharma loses patent case against Teva Pharmaceutical Industries of anti-sclerosis drugNatco Pharma has lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug,...
- Natco Pharma plunges after NY court verdictShares of Natco Pharma are witnessing selling pressure after a New York court ruled in favour of Teva in a patent case against the company.
- India Innovation Fund to invest 10 crore in SureWaves Media TechIndia Innovation Fund, best known as the only domestic venture fund that is backed by software services major TCS and telecom leader Airtel...
- Indian drug cos prepare a peptide mixAs blockbuster drugs are set to lose exclusivity in the US, Indian pharma companies are gearing up to tap the fast-growing generic peptide ...
Load More
